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A Missense Mutation in DHDDS, Encoding
Dehydrodolichyl Diphosphate Synthase, Is Associated with
Autosomal-Recessive Retinitis Pigmentosa in Ashkenazi Jews
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Retinitis pigmentosa (RP) is a heterogeneous group of inherited retinal degenerations caused by mutations in at least 50 genes. Using
homozygositymapping in Ashkenazi Jewish (AJ) patients with autosomal-recessive RP (arRP), we identified a shared 1.7Mbhomozygous
region on chromosome 1p36.11. Sequence analysis revealed a founder homozygous missense mutation, c.124A>G (p.Lys42Glu), in the
dehydrodolichyl diphosphate synthase gene (DHDDS) in 20 AJ patients with RP of 15 unrelated families. The mutation was not iden-
tified in an additional set of 109 AJ patients with RP, in 20 AJ patients with other inherited retinal diseases, or in 70 patients with retinal
degeneration of other ethnic origins. The mutation was found heterozygously in 1 out of 322 ethnically matched normal control indi-
viduals. RT-PCR analysis in 21 human tissues revealed ubiquitous expression of DHDDS. Immunohistochemical analysis of the human
retina with anti-DHDDS antibodies revealed intense labeling of the cone and rod photoreceptor inner segments. Clinical manifestations
of patients who are homozygous for the c.124A>G mutation were within the spectrum associated with arRP. Most patients had symp-
toms of night and peripheral vision loss, nondetectable electroretinographic responses, constriction of visual fields, and funduscopic
hallmarks of retinal degeneration. DHDDS is a key enzyme in the pathway of dolichol, which plays an important role in N-glycosylation
of many glycoproteins, including rhodopsin. Our results support a pivotal role of DHDDS in retinal function and may allow for new
therapeutic interventions for RP.Retinitis pigmentosa (RP; MIM 268000) is the most
common inherited retinal degeneration, with an estimated
worldwide prevalence of 1:4000.1–3 The disease is highly
heterogeneous and has several patterns of inheritance. At
present, 35 genetic loci have been implicated in nonsyn-
dromic autosomal-recessive RP (arRP), most of which
account for a few percent of RP cases each.
Although many of the early identified arRP genes were
excellent candidates for the disease when mutated, mainly
because of the function of the encoded protein (e.g.,
PDE6A4 [MIM 180071] and PDE6B5 [MIM 180072]), a large
proportion of the recently identified genes were not a priori
considered as candidates and were identified through
whole-genome linkage or homozygositymapping followed
by mutation screening of a large number of genes in the
linked intervals (e.g., EYS6 [MIM 612424] and SPATA77
[MIM609868]). Through those studies, a new class of genes
encoding proteins with housekeeping-like function (e.g.,
IDH3B [MIM604526] for arRP8 and splicing factors for auto-
somal-dominant RP9,10) have been identified and provided
new insight into processes that result in retinal degenera-
tion. The reason for the retina-specific phenotype caused
by mutations in these genes is still unclear.
The Ashkenazi Jewish (AJ) population was established by
Jews who originated in theMiddle East andmigrated to Eu-
rope, initially settling in Germany (the ‘‘Ashkenaz’’ region)
at or before the 4th century. The AJ lived in closed commu-
nities in European countries and developed a unique1Department of Ophthalmology, Hadassah-Hebrew University Medical Center,
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The Americaculture and language (named Yiddish, which is based on
a few different languages, including German, Hebrew,
and Aramaic). After the Holocaust, the population size
dropped from about 8.8 million individuals to only
2.8 million, and AJ immigrated out of Europe, mainly to
the United States and the emerging state of Israel. AJ
currently constitute the largest Jewish ethnic group in
both countries. A large amount of effort was directed to
study the genetic structure of the AJ population, in the
context of other Jewish ethnic groups and Middle Eastern
populations, at the Y chromosome,11,12 mitochondrial,13
and genomic14,15 levels. Although consanguineous
marriages are relatively uncommon among AJ (1.5% and
rapidly declining),16,17 most individuals who are affected
by a rare AR disease in this ethnic group are homozygous
for the disease-causing mutation, mainly because of
a high rate of intracommunity marriages.17 Therefore,
genetic analysis of hereditary diseases in the AJ population,
via homozygosity mapping, can be highly efficient.
In the present study, we used homozygosity mapping to
identify the cause of disease in AJ families with arRP. The
tenets of the Declaration of Helsinki were followed, and
prior to donation of a blood sample, informed consent
was obtained from all patients who participated in this
study. DNA was extracted from the index patient, as well
as from other affected and unaffected family members,
with the FlexiGene DNA kit (QIAGEN). Whole-genome
SNP analysis was initially performed on 11 patients withJerusalem 91120, Israel; 2Genetics Department, Rappaport Faculty of Medi-
Institute, University of Pennsylvania, Philadelphia, PA 19104, USA
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Table 1. Ashkenazi Jewish RP Families with the Homozygous








MOL0397 1 None NP
MOL0400 1 2:2 15.1
MOL0565 2 None 3.8
MOL0718 1 None 3.0
MOL0735 1 None 3.0
MOL0779 2 None 3.0
MOL0884 3 None 3.7
TB31/R54 1 None NP
TB61/R226 1 None 3.4
CHRD0262 2 None NP
CHRD0677 1 None 3.0
CHRD3323 1 None 3.2
CHRD3458 1 None 4.9
CHRD4047 2 None 3.8
CHRD5151 1 None 4.0
NP denotes not performed.
a Level of consanguinity is measured by the number of generations separating
the spouse from the common ancestor (e.g., 2:2 denotes first cousins).isolate or arRP who belong to eight different AJ families
with either the Affymetrix 250K or 6.0 microarrays, and
data analysis was performed with HomozygosityMapper.
Patients from three of the families (MOL0400, MOL0565,
and MOL0884; Table 1) had a shared homozygous region
on chromosome 1p36.11 encompassing ~2.32 Mb (Fig-
ure 1A). The shared homozygous region contains 56
protein coding genes, none of which is expressed exclu-
sively in the retina. While we were analyzing candidate
genes for mutations in the shared homozygous region,
Zuchner and collaborators reported the identification of
amissensemutation in an AJ family with arRP in a gene en-
coding a key enzyme in the terpenoid backbone synthesis
(S.Z. et al., abstract presented at The American Society of
Human Genetics annual meeting 2010). One of the genes
in the linked region on 1p36.11 was the dehydrodolichyl
diphosphate synthase gene (DHDDS; MIM 608172), en-
coding the dehydrodolichyl diphosphate synthase
(Figure 1B), which is predicted to take part in the above-
mentioned biochemical pathway.18 Using the Primer3
software,19 we designed primers flanking all coding exons
and exon-intron boundaries of DHDDS (accession number
NM_024887.2) and performed sequence analysis in the
three index patients. The analysis revealed a homozygous
transition, c.124A>G (Figure 1C), expected to result in
an amino acid (aa) substitution, p.Lys42Glu, in all three
index cases. Screening the mutation in a set of 322 ethni-
cally matched normal controls revealed one heterozygous
individual, thus indicating a carrier frequency of 0.3%
(95% confidence interval 0.07%–1.7%) in the AJ popula-
tion. We subsequently screened this mutation in a set of
121 AJ patients with RP, 20 AJ patients with other inherited
retinal diseases, and 70 non-AJ patients with retinal degen-
eration of other ethnic origins. The analysis revealed 12
additional index cases with RP that were homozygous for
the c.124A>G mutation, all of AJ descent. In addition,
we analyzed whole-genome SNP microarray data of
patients from 124 consanguineous families with RP or
Leber congenital amaurosis and identified 20 index cases
homozygous to the DHDDS region. DHDDS sequencing
analysis in these patients, as well as in an additional set
of 20 index RP patients from nonconsanguineous families,
did not reveal any potential pathogenic mutation. Statis-
tical analyses with Fisher’s exact test (based on allele
frequency: the mutation was found in 1 out of 644 chro-
mosomes in the control group versus 30 out of 246 chro-
mosomes in patients) and chi-square (based on genotype
frequency: the number of homozygous, heterozygous,
and wild-type individuals was 0, 1, and 321, respectively,
in controls versus 15, 0, and 108 in patients) showed
a significant difference between patient and control groups
(p < 0.001 for each comparison).
To better characterize the shared homozygous region, we
performed whole-genome SNP analysis (with Affymetrix
6.0 arrays) on nine additional homozygous index cases
(see Table 1 and Table S1 available online; whole-genome
SNP array genotyping data are available by request). This208 The American Journal of Human Genetics 88, 207–215, Februaryallowed us to analyze the homozygous region in a total
of 15 homozygous patients and 1 unaffected sibling repre-
senting 12 different AJ families. The analysis revealed an
identical shared region of 1.68 Mb (26.4–28.08) on chro-
mosome 1, harboring 41 protein-coding genes, including
DHDDS. The shared haplotype contains 244 homozygous
SNPs representing a founder RP-associated haplotype in
the AJ population. No other shared homozygous regions
(over 1 Mb) could be detected in this set of patients, nor
in the original three families used for homozygosity
mapping.
The c.124A>G mutation affects a conserved amino acid
residue (Lys42; Figure 1D) located in close proximity to
a binding site of farnesyl diphosphate. The mutation
substitutes the wild-type basic aa lysine with an acidic
one, glutamic acid. The predicted effect of this substitu-
tion, with different tools designed to predict functional
effects of missense changes, is not conclusive. Some tools
did not predict a functional effect (e.g., PMUT: a neutral
score of 0.4429; SAP: a neutral score of 0.53), whereas other
tools did predict a functional effect (e.g., PolyPhen2:
possibly damaging with a score of 0.206; SIFT: an intol-
erant score of 0.03; MutationTaster: a disease-causing
prediction with a probability of 0.998).
In summary, the p.Lys42Glu DHDDS mutation was
identified in 15 (out of 123, 12%) AJ RP index patients in
our cohort, and it cosegregated with the disease when addi-




Figure 1. Homozygosity Mapping, Gene
Structure, and the Mutation Identified in
DHDDS
(A) The chromosomal region harboring
the homozygous haplotype at chromo-
some 1 (top). Rulers are based on the
February 2009 USCS genome build
(hg19). The set of horizontal bars repre-
sents the homozygous region in the three
different families, as identified by whole-
genome SNP analysis. The family number
is shown on the left. The region flanked
by SNP markers rs3924468 and
rs11247703, covering 2.32 Mb between
25.8 and 28.1 Mb on chromosome 1, was
considered the shared homozygous region.
(B) Intron-exon structure of DHDDS and
known or predicted protein domains. The
structure of DHDDS is depicted (top) with
exons marked as black rectangles (wider
for the coding region). The location of
the c.124A>G (p.Lys42Glu) missense
mutation is marked below exon 3. Known
or putative domains of the DHDDS
enzyme are depicted (bottom), with an
asterisk pointing to the mutation position.
(C) Sequence chromatograms of part of
DHDDS exon 3 of a homozygous mutant
and a wild-type individual. The
c.124A>G mutation (boxed) changes an
AAG codon to GAG (p.Lys42Glu).
(D) An amino acid sequence alignment of
DHDDS including position 42 (boxed).
The aa types are color-coded: small aa in
red, acidic in blue, basic in magenta, and
hydroxyl þ amine þ basic in green.Aiming to clinically characterize patients with the
p.Lys42Glu DHDDS mutation, we performed full ophthal-
mologic examinations, electroretinography (ERG), kinetic
visual fields, color vision testing, optical coherence tomog-
raphy (OCT), and autofluoresence (AF) imaging, as previ-
ously described.20–22 Clinical evaluation of 18 patients
showed a spectrum of findings (Table S2). The patients
had visual acuity that ranged from light perception to
20/20 (LogMAR 0.0; Table S2). Funduscopic findings at
various disease stages included waxy appearance of the
optic nerve head, attenuation of retinal blood vessels,
and bone spicule-like pigmentation (Figure S1). OCT
imaging in early disease showed preserved central retinal
photoreceptors but a decline in photoreceptor layer thick-
ness with distance from the fovea (Figure 3E), and occa-
sionally the presence of cystoid macular edema
(Figure S2). Kinetic visual fields revealed reduced periph-
eral function in the youngest patients studied and only
small central islands of vision remaining later in lifeThe American Journal of Human Gen(Figures 3A and 3B and Figure S3).
ERG responses were nondetectable
in most patients (Table S2).
The natural history of the disease in
family MOL0884 can be gleaned from
serial ocular data acquired from thesecond to the fourth decades of life in the three affected
siblings (Figure 3). Symptoms occurred during the latter
part of the second decade of life in all three siblings, and
these related to decreasing night and side vision; loss of
reading (central) vision was not an early complaint. Visual
field extent was quantified via kinetic perimetry to a large
target (Figures 3A and 3B); fields became progressively
reduced with only a small central island remaining by ages
21–24. Best-corrected visual acuity had a more prolonged
time course of loss but was 20/200 or worse in two siblings
by age 30–31 (Figure 3C). Rod-mediated vision was
measurable via dark-adapted chromatic sensitivities in
all three patients at younger ages, but this progressively
diminished until only cone-mediated function was detect-
able (Figure 3D). Photoreceptor topography in a wide
expanse of central retina (Figure 3E) revealed that by
the fourth decade of life, there was only a markedly
thinned photoreceptor layer remaining in and around
the fovea; in two of three siblings, photoreceptors wereetics 88, 207–215, February 11, 2011 209
Figure 2. Cosegregation of Mutation
and Phenotype in Identified Families
The family number is indicated above the
corresponding family tree. Filled symbols
represent affected individuals, whereas
clear symbols represent unaffected indi-
viduals. Generation numbers are depicted
on the left. TheDHDDS genotype is shown
below recruited individual symbols: M/M
denotes homozygous for the mutation;
M/þ denotes heterozygous for the muta-
tion; þ/þ denotes homozygous for the
wild-type allele.not detectable surrounding the foveal region. Patient
MOL0884-4 (II:4 in Figure 2) also had a locus of detect-
able photoreceptors nasal to the optic nerve head
(Figure 3E, P4), and this correlated with an area of limited
rod sensitivity by dark-adapted psychophysical testing
(Figure 3D). Near-infrared autofluoresence imaging
showed islands of preserved retinal pigment epithelium
corresponding in retinal location to the regions of
preserved photoreceptors (Figure 3E, insets). Two of the
patients were imaged with wide-angle view, and bone
spicule-like pigment was visible (Figure S2). In addition,
both parents and an asymptomatic sibling in family
MOL0884 were examined clinically, with kinetic perimetry
and standard ERGs. No abnormalities were detected, with
the exception of a borderline rod ERG amplitude in the
father’s recording.
DHDDS contains eight coding exons along a genomic
region of ~37 kb18 and is known to produce a few splice
variants.23 No data, however, are available on its expres-
sion or function in the retina. To verify the retinal expres-
sion of DHDDS, we isolated RNA from the human retina
with TRI-reagent (Sigma-Aldrich) and synthesized cDNA
with the Verso cDNA kit (Thermo) in accordance with
the manufacturer’s protocol. PCR-specific primers (Table
S3) were designed with Primer3, and RT-PCR analysis was
performed with three primer sets that were designed to
amplify different parts of the cDNA molecules (Figure 4A).
The analysis confirmed the expression of the full-length
transcript in the retina, as well as three alternatively spliced
variants, two of which are in-frame and are likely to encode
a protein (Figure 4A): a NAGNAG sequence24 in the
acceptor splice site of intron 8 and a transcript in which
exon 6 is skipped. The third transcript had a frameshift
addition of 23 nucleotides because of a cryptic acceptor
splice site in intron 3, resulting in a premature stop codon
(Figure 4A) within exon 4, and is therefore likely to be
degraded by the nonsense-mediated mRNA decay or, alter-
natively, to produce a nonfunctional protein. Expressed210 The American Journal of Human Genetics 88, 207–215, February 11, 2011sequence tags (ESTs) representing
these variants were previously depos-
ited in GenBank. To better charac-
terize the distribution of DHDDS in
human tissues, we performed RT-
PCR analysis on cDNAs that weresynthesized from RNA derived from 20 different human
tissues (Clontech; category 636643, lot 8101369A), as
well as the human retina (Figure 4B). Human PGM1
(MIM 171900) was used as a control. Ubiquitous expres-
sion of DHDDS was observed, with a band of higher inten-
sity in the retinal sample as compared to other tissues
(Figure 4B, right lane). The ubiquitous expression supports
data obtained with RNA blot in a set of tissues that did not
include ocular ones.18
To study the localization of the DHDDS enzyme in the
human retina, we performed immunohistological studies
with two commercially available anti-DHDDS antibodies
(HPA026721 and HPA026727 [rabbit polyclonal, Sigma
Life Science] at a final concentration of 1:15 and 1:175,
respectively; secondary antibody Cy2-conjugated
donkey anti-rabbit IgG [1:200, Jackson ImmunoResearch
Laboratories]). Prominent staining of the inner segments
of photoreceptors was identified, which differed between
rod and cone photoreceptors (Figure 5B, compared to the
hematoxylin and eosin staining in Figure 5A and the nega-
tive control section in Figure 5C). Although the cone inner
segments demonstrated a uniform signal, only the ellip-
soid (distal region) and myoid (proximal region) of the
rod photoreceptor inner segments were labeled, whereas
the central part had much lower fluorescence (Figures 5D
and 5E). The labeling of the cone inner segments is in
accordance with a uniform distribution of cone inner
segment organelles. In the rod inner segments, the myoid
region contains the cellular protein synthesis machinery
(including the Golgi apparatus and the endoplasmatic
reticulum) in which N-glycosylation takes part, and the
ellipsoid region contains mainly the mitochondria, which
was shown to contain dolichol and dolichyl phos-
phate.25,26 The subcellular localization of DHDDS in rod
photoreceptors is therefore in accordance with the ex-
pected distribution of the enzyme. DHDDS-positive stain-
ing was also evident in the basal aspect of retinal pigment
epithelium cells (Figure 5E), and a weak staining was
Figure 3. Ocular Phenotype of Three
Siblings Who Are Homozygous for the
DHDDS c.124A>G Mutation
(A) Visual field extent (kinetic perimetry
with V-4e test target) expressed as
a percentage of normal mean and plotted
as a function of age in the three siblings
of family MOL0884.
(B) Visual fields (V-4e, I-4e test targets) at
different ages showing progressive periph-
eral vision loss.
(C) Visual acuity (expressed in logMAR
units) as a function of age in the patients.
(D) Dark-adapted static perimetric profiles
across the horizontal meridian with
a 500 nm stimulus in the three siblings.
Data span a minimum of 1.5 decades in
each patient. Based on two-color (500 nm
and 650 nm) dark-adapted perimetry,
photoreceptor mediation was determined
for each test locus at the earliest (blue
letters) and latest (red letters) ages studied.
The following abbreviations are used: R,
rod-mediated; M, mixed rod- and cone-
mediated; C, cone-mediated; N, nasal; T,
temporal visual field. Gray represents
normal limits (mean 5 2 standard devia-
tion). Hashed band is the location of the
physiological blind spot.
(E) Photoreceptor layer thickness topog-
raphy mapped to a pseudocolor scale
(shown above normal map) in a normal
subject and in the three affected siblings.
Insets: near-infrared excited autofluores-
cence imaging of melanin fluorophore
distribution to estimate retinal pigment
epithelium (RPE) layer health.evident in other retinal layers (Figure 5B). The labeling
pattern of DHDDS in the human retina is compatible
with its function in dolichol metabolism (expected to
occur in the photoreceptor inner segments), as well as
the phenotype obtained (photoreceptor degeneration) as
a result of the mutation identified in DHDDS.
Dehydrodolichyl diphosphate (Dedol-PP) synthase is
a highly conserved enzyme that can be found in all animal
species, as well as in plants and bacteria. It catalyzes cis-
prenyl chain elongation to produce the polyprenyl back-
bone of dolichol (Figure 6A). The humanDedol-PP enzyme
was reported to be able to complement for the lack of the
orthologous enzyme in a yeast mutant strain.18 In
mammals, dolichol is present in most tissues, with rela-
tively high levels in human tissues compared to other
animals,27,28 and the levels of dolichol compounds are re-
ported to increase substantially with age.29 Dolichyl pyro-
phosphate plays an important role as a glycosyl carrier in
the biosynthesis of the N-linked oligosaccharide chains
of freshly synthesized glycoproteins (Figure 6B).
Direct proof for the activity of the dolichol pathway in
the retina has been obtained by classical biochemical
methods (reviewed by 30), as well as by measuring the
absolute rate of dolichyl phosphate (Dol-P) synthesis in
the retina.31 Protein N-glycosylation is a fundamental bio-
logical process (reviewed by 32–34) and is a requisite forThe Americamaintaining normal structure and function of the retina
(reviewed by 35,36). The most important and abundant
rod photoreceptor protein, rhodopsin, is composed of
a single polypeptide chain to which two unusually
short N-linked oligosaccharide chains are covalently
coupled37–39 at positions N-2 and N-15 (Figure 6B). Exper-
iments in the 1980s with tunicamycin (a specific inhibitor
of theN-glycosylation pathway; Figure 6B)32 demonstrated
aberrant photoreceptor outer segment membrane
morphogenesis in vitro in isolated Xenopus retinas main-
tained in short-term organ culture,40 as well as retinal
degeneration in living frogs.41 In the former study, intraoc-
ular injection of tunicamycin produced a progressive RP-
like phenotype in which shortening of rod outer segments
occurred, accompanied by decreased ERG amplitudes and
disruption of the rod outer segment membrane
assembly.41 It should be noted that the ocular phenotype
in these animals was restricted to the photoreceptors,
although the concentration of tunicamycin was expected
to be the lowest in this layer.41 The photoreceptor-specific
phenotype might be explained by the observation that the
highest activity of the lipid-intermediate pathway of glyco-
protein synthesis in the retina is in the photoreceptor
layer.42 Within the eye, the phenotype obtained in these
animals is therefore in concordance with the RP pheno-
type in patients with the DHDDS mutation.n Journal of Human Genetics 88, 207–215, February 11, 2011 211
Figure 4. DHDDS Transcripts and RT-PCR
Analysis in Human Tissues
(A) DHDDS can produce different tran-
scripts through alternative splicing. The
scheme represents the full-length open
reading frame (ORF) of DHDDS (top), as
well as alternatively spliced transcripts
identified in this study: skipping of exon
6 (middle) and recognition of a cryptic
acceptor site within intron 3 (bottom,
blue box), leading to the addition of 23
nucleotides. Arrows represent the location
and direction of primers used for RT-PCR
(see also Table S3). The NAGNAG
sequence in exon 9 represents an alterna-
tive usage of either the first or second
NAG sequence as an acceptor splice site
of intron 8. Ex denotes exon, Int denotes
intron, PTC denotes premature termina-
tion codon. It should be noted that a
transcript in which exon 5 is skipped
has been deposited in GenBank, but we were not able to verify it in any of the analyzed tissues.
(B) The expression level of DHDDS in 21 tissues is depicted. Two sets of primers were used to amplify DHDDS: set 1 amplified exons 4
trough 6 (F4-R6), and set 2 primers amplified exons 5 through 7 (F5-R7). PGM1 amplification served as a control for cDNA amount
used in the PCR reaction (set 3). The lower faint band in set 2 could be observed in all tissues, and sequence analysis revealed skip-
ping of exon 6.It is unclear, however, why the phenotype in the human
patients is restricted to the retina and why no dysfunction
is evident in other organs. Disruption of the N-glycosyla-
tion pathway in humans, as a result of loss-of-function
mutations in several genes, is known to cause a set of
syndromes known as congenital disorders of N-glycosyla-
tion.43 It is logical to assume that the mutation we identi-
fied in DHDDS alters, rather than abolishes, enzymatic
function, perhaps either by reducing the level of DHDDS212 The American Journal of Human Genetics 88, 207–215, Februaryprotein or by preventing requisite interactions between
DHDDS and a photoreceptor-specific protein. Reduced
protein levels might have a mild effect on other organs
but might severely affect rhodopsin function and/or intra-
cellular trafficking, leading to progressive photoreceptor
degeneration over time (Figure 6C). Alternatively, the
photoreceptor degeneration might not be related to alter-
ation in opsin N-glycosylation, but rather to a toxic accu-
mulation of isoprenoid compounds (Figure 6C). DolicholFigure 5. DHDDS Expression in the
Human Retina
(A) Hematoxylin-Eosin stained section of
a normal human retina, with identifica-
tion of the different retinal layers. The
following abbreviations are used: GCL,
ganglion cell layer; IPL, inner plexiform
layer; INL, inner nuclear layer; OPL, outer
plexiform layer; ONL, outer nuclear layer,
containing the photoreceptor nuclei;
IS, inner segments of photoreceptors; OS,
outer segments of photoreceptors; RPE,
retinal pigment epithelium layer.
(B and C) Low-magnification images of
anti-DHDDS antibody-labeled (B, in green
fluorescence) and control (C, no primary
antibody applied) retinal sections. Note
prominent labeling of the rod and cone
inner segments. Yellow color of the RPE
layer is due to autofluorescence of these
cells (original magnification 203). Scale
bar represents 100 mm.
(D and E) Higher-magnification images of
the photoreceptor-RPE region. Note
segmental staining of the ellipsoid (red
arrow) and myoid (white arrow) of the
rod photoreceptor inner segments (orig-
inal magnification 403 with digital
zoom). Scale bar represents 25 mm. A repre-
sentative cone inner segment is marked by
a yellow star.
11, 2011
Figure 6. The Function of the DHDDS Enzyme and Possible Mechanisms Underlying DHDDS-Related Retinal Degeneration
(A) DHDDS is a key enzyme in dolichol biosynthesis, which catalyzes cis-prenyl chain elongation to produce the polyprenyl backbone of
dolichol. It is required for two enzymatic steps (arrows) along the dolichol pathway.
(B) Schematic representation of the role of dolichol in N-glycosylation. Dolichol is a membrane-bound glycosyl carrier and plays an
important role in the biosynthesis of the N-linked oligosaccharide chains of glycoproteins. The two arrows represent multiple steps
that are not shown here. N-glycosylation of the opsin molecule is schematically represented on the right. The ribosome (oval shape)
synthesizes fresh opsin molecules with two sites of N-glycosylation (ASN) at the N terminus (positions 2 and 15). Dol-PP transfers
the oligosaccharide chain to these sites to glycosylate the opsin molecule (based on 49).
(C) Scheme of putative mechanisms by which the DHDDSmutation could lead to retinal degeneration. In the top panel, the possibility
that themutation causes a hyperactivity in the enzymatic function of DHDDS leading to excessive accumulation of Dol-P and/or Dol-PP,
because of ‘‘overflow’’ of the N-glycosylation pathway, is shown. These substances might be toxic to the photoreceptor cell, causing
photoreceptor degeneration. Alternatively, the mutation can by hypormorph, leading to reduced enzymatic function of DHDDS.
This might in turn reduce N-glycosylation levels, producing a certain amount of nonglycosylated, and therefore nonfunctional, opsin
molecules, leading to photoreceptor degeneration. Either of the proposed two mechanisms might mimic the retinal degeneration
phenotype cause by the inhibitor of N-glycosylation followed by exposure to tunicamycin (panel B).accumulation has been reported in neuronal ceroid lipo-
fuscinosis,44 in which retinal degeneration occurs, and
alteration of dolichol/Dol-P levels has been reported in
patients with Alzheimer disease.45–48
Our finding of a prevalent arRP-associated mutation in
a specific ethnic group has practical implications for
genetic testing in AJ RP patients. In this genetically hetero-
geneous condition in which each gene accounts for a small
fraction of cases, the relatively high frequency of this
DHDDS mutation (over 10% of AJ RP patients) points to
a useful modification of the testing strategy for RP. In
simplex and multiplex RP patients with AJ ancestry, the
p.Lys42Glu DHDDS mutation should be one of theThe Americascreening targets. Moreover, the identification of a DHDDS
mutation may become the first step toward recommenda-
tion of specific therapeutic options for this currently incur-
able progressive disease leading to blindness.
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